

ASX Announcement

25 February 2021

Regeneus (ASX: RGS) Company Update Investor Webcast Notification

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today advises it will be conducting a live webcast and Q&A with Regeneus CEO Karolis Rosickas on Wednesday 3 March at 11:00am Australian Eastern Daylight Time (AEDT).

Investors are invited to join the session where Mr. Rosickas will provide an update on the Company's technology and ongoing strategy. Please note, the webinar will not cover financial updates.

To register for the webcast, please follow this link:

https://us02web.zoom.us/webinar/register/WN_YyKYF3USS0WusNbnBlafAQ

Investors are invited to submit questions relating to the Company's technology ahead of the webcast by emailing WE-AURegeneus@we-worldwide.com.

Registered participants will receive a confirmation email containing the Zoom access link and alternative phone dial-in details.

- ENDS -

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza™ and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

WE Communications

T: (03) 8866 1200

E: WE-AURegeneus@we-worldwide.com